ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Biodesix Inc

Biodesix Inc (BDSX)

1.77
0.05
(2.91%)
Closed July 16 4:00PM
1.77
0.00
( 0.00% )
Pre Market: 7:02AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
1.77
Bid
1.61
Ask
1.71
Volume
15
0.00 Day's Range 0.00
1.03 52 Week Range 2.21
Market Cap
Previous Close
1.77
Open
-
Last Trade
5
@
1.77
Last Trade Time
07:02:07
Financial Volume
-
VWAP
-
Average Volume (3m)
160,689
Shares Outstanding
114,685,783
Dividend Yield
-
PE Ratio
-3.89
Earnings Per Share (EPS)
-0.45
Revenue
49.09M
Net Profit
-52.15M

About Biodesix Inc

Biodesix Inc is a data-driven diagnostic solutions company. Its artificial intelligence-based platform helps to discover, develop, and commercialize solutions for clinical unmet needs, with a focus on lung disease. It provides biopharmaceutical companies with services that include diagnostic researc... Biodesix Inc is a data-driven diagnostic solutions company. Its artificial intelligence-based platform helps to discover, develop, and commercialize solutions for clinical unmet needs, with a focus on lung disease. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. Show more

Sector
Medical Laboratories
Industry
Medical Laboratories
Headquarters
Wilmington, Delaware, USA
Founded
1970
Biodesix Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker BDSX. The last closing price for Biodesix was $1.77. Over the last year, Biodesix shares have traded in a share price range of $ 1.03 to $ 2.21.

Biodesix currently has 114,685,783 shares outstanding. The market capitalization of Biodesix is $202.99 million. Biodesix has a price to earnings ratio (PE ratio) of -3.89.

BDSX Latest News

Biodesix Named to Inc. Magazine’s 2024 “Best Workplaces”

Awarding Excellence in Company Culture Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazine’s Best Workplaces list. The...

Biodesix to Participate in Two Investor Conferences in June

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.1710.6251.61.771.5903800461.70348908CS
40.159.259259259261.621.771.452754431.61486688CS
120.4938.281251.281.771.21606891.55901015CS
26-0.11-5.851063829791.882.211.151595961.57077603CS
520.6253.91304347831.152.211.031182731.58012994CS
156-9.33-84.054054054111.111.26050.9551684942.43048546CS
260-11.82-86.975717439313.5931.990.9551637614.88358374CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ADTXAditxt Inc
$ 3.02
(88.76%)
4.35M
SHIMShimmick Corporation
$ 3.01
(45.41%)
2.39M
SOHOSotherly Hotels Inc
$ 1.78
(40.16%)
6
LCFYLocafy Ltd
$ 6.80
(24.77%)
502.59k
APVOAptevo Therapeutics Inc
$ 0.4159
(24.15%)
20.06M
FIVEFive Below Inc
$ 86.07
(-15.68%)
84.35k
OCULOcular Therapeutix Inc
$ 7.26
(-13.57%)
5.53k
QXOQXO Inc
$ 47.51
(-12.83%)
598
GRNQGreenpro Capital Corporation
$ 1.20
(-12.41%)
2.14k
OCTOEightco Holdings Inc
$ 0.4687
(-11.06%)
40.64k
APVOAptevo Therapeutics Inc
$ 0.4159
(24.15%)
20.06M
CEROCERo Therapeutics Holdings Inc
$ 0.2037
(4.46%)
11.61M
CDTConduit Pharmaceuticals Inc
$ 0.275
(9.52%)
7.66M
MLGOMicroAlgo Inc
$ 3.38
(19.01%)
5.78M
NVDANVIDIA Corporation
$ 121.01
(-4.23%)
4.66M

BDSX Discussion

View Posts
AJ Freely AJ Freely 1 year ago
$BDSX - Up 12%/ Current Price $1.34.
Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules
👍️0
1hot toddy 1hot toddy 2 years ago
WOOOOOOW 130K SHARES BUY NOW 2.6 MIL SHARE BUY $

3 MILLION $ BUY $$$$$$$$$$$$$$$$$$$$$$
👍️0
Leg58 Leg58 2 years ago
Lots if potential but will public offering dilute price?
👍️0
Leg58 Leg58 2 years ago
Lots if potential but will public offering dilute price?
👍️0
subslover subslover 2 years ago
Earnings look good.
👍️0
subslover subslover 2 years ago
Earnings look good.
👍️0
MiamiGent MiamiGent 2 years ago
BDSX Has news this morning!

The contract covers the company’s entire lung diagnostic portfolio: Nodify XL2®, Nodify CDT®, VeriStrat®, GeneStrat® ddPCR, and GeneStrat NGS™ testing.

https://investors.biodesix.com/news-releases/news-release-details/biodesix-awarded-us-federal-supply-schedule-contract-its

https://stockcharts.com/h-sc/ui?s=BDSX
👍️0
carusso carusso 2 years ago
Not so much...
👍️0
crudeoil24 crudeoil24 2 years ago
LET'S GO BDSX !!!!!
👍️0
crudeoil24 crudeoil24 2 years ago
Biodesix to Participate in Two Upcoming Investor Conferences in September
6:00 am ET September 6, 2022 (BusinessWire) Print
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences:

Morgan Stanley 20th Annual Global Healthcare Conference Date: Tuesday, September 13, 2022 at 9:10 a.m. ET Format: Fireside Chat and 1x1 meetings Location: Sheraton Hotel, New York, NY Details: The fireside chat will be webcast live and available for replay under "News & Events" in the Investors section of the Company's website at www.biodesix.com.

H.C. Wainwright 24th Annual Global Investment Conference Dates: September 12-14, 2022 Format: 1x1 meetings Location: Lotte New York Palace Hotel, New York, NY
👍️0
crudeoil24 crudeoil24 2 years ago
Biodesix, Inc. is a United States-based company engaged in developing and commercializing blood-based diagnostic tests for oncology. The Company’s product Biodesix Lung Reflex integrates genomic and proteomic blood-based results to reveal both sides of lung cancer. Its GeneStrat test offers blood-based mutation results within 72 hours for patients with non-small cell lung cancer (NSCLC). Its VeriStrat testing provides blood-based predictive and prognostic proteomic information with (NSCLC) who test negative for estimated glomerular filtration rate (EGFR) mutations (EGFR wild-type) or whose EGFR mutation status is unknown.
👍️0
Leg58 Leg58 2 years ago
US based company is quietly trending up. IMHO.
GLTA
👍️0

Your Recent History

Delayed Upgrade Clock